| 2,6-substituted chroman derivatives useful as beta-3 adrenoreceptor agonists -> Monitor Keywords |
|
|
  2,6-substituted chroman derivatives useful as beta-3 adrenoreceptor agonistsUSPTO Application #: 20050215594Title: 2,6-substituted chroman derivatives useful as beta-3 adrenoreceptor agonists Abstract: This invention relates to novel 2,6-substituted chroman derivatives which are useful in the treatment of beta-3 adrenoreceptor-mediated conditions. (end of abstract) Agent: Jeffrey M. Greenman - West Haven, CT, US Inventors: Stephen J. O'Connor, Gaetan H. Ladouceur, William H. Bullock, Ann-Marie Campbell, Miao Dai, Robert Dally, Jacques Dumas, Holia N. Hatoum-Mokdad, Uday Khire, Wendy Lee, Qingjie Liu, Derek B. Lowe, Steven R. Magnuson, Ning Qi, Tatiana E. Skelekhin, Quanrong Shen, Roger A. Smith, Ming Wang USPTO Applicaton #: 20050215594 - Class: 514337000 (USPTO) Related Patent Categories: Drug, Bio-affecting And Body Treating Compositions, Designated Organic Active Ingredient Containing (doai), Heterocyclic Carbon Compounds Containing A Hetero Ring Having Chalcogen (i.e., O,s,se Or Te) Or Nitrogen As The Only Ring Hetero Atoms Doai, Hetero Ring Is Six-membered Consisting Of One Nitrogen And Five Carbon Atoms, Additional Hetero Ring Containing, The Additional Hetero Ring Is One Of The Cyclos In A Polycyclo Ring System The Patent Description & Claims data below is from USPTO Patent Application 20050215594. Brief Patent Description - Full Patent Description - Patent Application Claims
[0001] This application claims benefit of U.S. Provisional Application Ser. No. 60/285,719, filed Apr. 23, 2001, and U.S. Provisional Application Ser. No. 60/324,518, filed on Sep. 26, 2001, the contents of which are incorporated herein by reference in their entirety. FIELD OF THE INVENTION [0002] This invention relates to novel chroman compounds, pharmaceutical compositions containing such compounds, and methods of treating beta-3 adrenoreceptor-mediated conditions with such compositions. BACKGROUND OF THE INVENTION [0003] Adrenoreceptors, or adrenergic receptors, are sites on effector organs that are innervated by postganglionic adrenergic fibers of the sympathetic nervous system, and are classified as either alpha-adrenergic or beta-adrenergic receptors. Alpha-adrenergic receptors respond to norepinephrine and to such blocking agents as phenoxybenzamine and phentolamine, whereas beta-adrenergic receptors respond to epinephrine and to such blocking agents as propranolol. [0004] Beta-adrenergic receptors are sub-classified as beta-1, beta-2, and beta-3 adrenoreceptors. Generally, beta-1 stimulation causes cardiostimulation, whereas beta-2 stimulation causes bronchodilation and vasodilation. [0005] Beta-3 receptors are found on the cell surface of both white and brown adipocytes where their stimulation promotes both lipolysis and energy expenditure. Agonists of beta-3 adrenoreceptors are known to be useful in the treatment of hyperglycemia (diabetes) and obesity in mammals, as well as in the treatment of gastrointestinal disorders and neurogenetic inflammation (U.S. Pat. No. 5,561,142). Additionally, they are known to lower triglyceride and cholesterol levels and to raise high-density lipoprotein levels in mammals (U.S. Pat. No. 5,451,677). Accordingly, they are useful in the treatment of conditions such as hypertriglyceridemia, hypercholesterolemia, and in lowering high-density lipoprotein levels. They also may be useful in treating patients with Syndrome X, impaired fasting glucose, and/or impaired glucose tolerance, as well as in the treatment of atherosclerotic and cardiovascular diseases and related conditions. [0006] Additionally, it is also believed that the compounds of this invention are effective in the treatment of ocular hypertension and glaucoma, and in the treatment of urinary disorders including pollakiuria and incontinence, as well as in the treatment of prostate disease and as topical anti-inflammatory agents. [0007] It has now been found that certain novel chroman derivatives are effective as beta-3 agonists and are useful in the treatment of beta-3 adrenoreceptor-mediated conditions. DESCRIPTION OF THE INVENTION [0008] 1 [0009] wherein, [0010] R is independently [0011] hydroxy, [0012] oxo, [0013] halo, [0014] cyano, [0015] nitro, [0016] C.sub.1-C.sub.10 alkyl, [0017] C.sub.1-C.sub.10 haloalkyl, [0018] CF.sub.3, [0019] NR.sup.1R.sup.1, [0020] SR.sup.1, [0021] OR.sup.1, Continue reading... Full patent description for 2,6-substituted chroman derivatives useful as beta-3 adrenoreceptor agonists Brief Patent Description - Full Patent Description - Patent Application Claims Click on the above for other options relating to this 2,6-substituted chroman derivatives useful as beta-3 adrenoreceptor agonists patent application. ###  How KEYWORD MONITOR works... a FREE service from FreshPatents1. Sign up (takes 30 seconds). 2. Fill in the keywords to be monitored. 3. Each week you receive an email with patent applications related to your keywords. Start now! - Receive info on patent apps like 2,6-substituted chroman derivatives useful as beta-3 adrenoreceptor agonists or other areas of interest. ### Previous Patent Application: Methods treating tumors with thalidomide Next Patent Application: Indazole derivatives and methods for using the same Industry Class: Drug, bio-affecting and body treating compositions ### FreshPatents.com Support Thank you for viewing the 2,6-substituted chroman derivatives useful as beta-3 adrenoreceptor agonists patent info. IP-related news and info Results in 5.86981 seconds Other interesting Feshpatents.com categories: Tyco , Unilever , Warner-lambert , 3m |
||
